Sarasota, FL – According to filings with the U.S. Securities and Exchange Commission, DalCor Pharmaceuticals is raising $2,845,541.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Fouzia Laghrissi-Thode played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About DalCor Pharmaceuticals

DalCor is pioneering precision medicine for cardiovascular disease. The company is developing dalcetrapib, a unique cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile to maximize clinical benefit. DalCor has world-wide exclusive rights to develop and commercialize dalcetrapib and CETP inhibitors for the treatment of cardiovascular diseases in patients who have one or more improved response genotypes  through at least  2034. The company has a global presence with offices in Canada, Switzerland, the United Kingdom, and the United States.

To learn more about DalCor Pharmaceuticals, visit http://www.dalcorpharma.com/

Contact:
Fouzia Laghrissi-Thode, Chief Executive Officer
514-501-5234
https://www.linkedin.com/in/fouzia-laghrissi-thode-951b60198/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved